| 1 |
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China,2022 [J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
|
| 2 |
Sanz-pamplona R, Cordero D, Berenguer A, et al. Gene expression differences between colon and rectum tumors [J]. Clin Cancer Res, 2011,17(23): 7303-7012.
|
| 3 |
Mik M, Berut M, Dziki L, et al. Right- and left-sided colon cancerclinical and pathological differences of the disease entity in one organ [J].Arch Med Sci, 2017, 13(1): 157-162.
|
| 4 |
Shen H, Yang J, Huang Q, et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers [J].World J Gastroenterol, 2015, 21(21): 6470-6478.
|
| 5 |
Holch J W, Ricard I, Stintzing S, et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials [J]. Eur J Cancer, 2017, 70: 87-98.
|
| 6 |
Salem ME, Weinberg BA, Xiu J, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers [J]. Oncotarget,2017, 8(49): 86356-86368.
|
| 7 |
Imperial R, Ahmed Z, Toor OM, et al. Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles [J]. Mol Cancer, 2018,17(1): 177.
|
| 8 |
夏金红, 顾晋. 左右半结肠癌与programmed Death-1 信号通路[J/OL]. 中华结直肠疾病电子杂志, 2019, 8(6): 553-559.
|
| 9 |
Reily C, Stewart TJ, Renfrow MB, et al. Glycosylation in health and disease [J]. Nat Rev Nephrol, 2019, 15(6): 346-366.
|
| 10 |
Pearce OM, Läubli H. Sialic acids in cancer biology and immunity[J]. Glycobiology, 2016, 26(2): 111-128.
|
| 11 |
Lin Y, Lubman DM. The role of N-glycosylation in cancer [J]. Acta Pharm Sin B, 2024, 14(3): 1098-1110.
|
| 12 |
Stanczak MA, Rodrigues Mantuano N, Kirchhammer N, et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade [J]. Sci Transl Med, 2022, 14(669):eabj1270.
|
| 13 |
Bhide Gp, Colley KJ. Sialylation of N-glycans: mechanism, cellular compartmentalization and function [J]. Histochem Cell Biol, 2017, 147(2):149-174.
|
| 14 |
Perez S, Fu CW, Li WS. Sialyltransferase inhibitors for the treatment of cancer Metastasis: current challenges and future perspectives [J].Molecules (Basel, Switzerland), 2021, 26(18): 5673.
|
| 15 |
Cheng J, Wang R, Zhong G, et al. ST6GAL2 Downregulation inhibits cell adhesion and invasion and is asociated with improved patient survival in breast cancer [J]. Onco Targets Ther, 2020, 13: 903-914.
|
| 16 |
Jame-Chenarboo F, Ng HH, Macdonald D, et al. High-throughput analysis reveals miRNA upregulating α-2,6-sialic acid through direct miRNAmRNA interactions [J]. ACS Cent Sci, 2022, 8(11): 1527-1536.
|
| 17 |
Liang A, Zhou B, Sun W. Integrated genomic characterization of cancer genes in glioma [J]. Cancer Cell Int, 2017, 17: 90.
|
| 18 |
Liang L, Xu J, Wang M, et al. LncRNA HCp5 promotes follicular thyroid carcinoma progression via miRNAs sponge [J]. Cell Death Dis, 2018,9(3): 372.
|
| 19 |
Liu R, Yu X, Cao X, et al. Downregulation of ST6GAL2 correlates to liver inflammation and predicts adverse prognosis in hepatocellular carcinoma[J]. J Inflamm Res, 2024, 17: 565-580.
|
| 20 |
Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location [J]. Ann Intern Med, 1990, 113(10):779-788.
|
| 21 |
Sinicrope FA, Mahoney MR, Yoon HH, et al. Analysis of molecular markers by anatomic tumor dite in dtage III colon carcinomas from adjuvant chemotherapy trial NCCTG N0147 (Alliance) [J]. Clin Cancer Res, 2015, 21(23): 5294-5304.
|
| 22 |
Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum [J]. Gut, 2012,61(6): 847-854.
|
| 23 |
Cao K, Zhang G, Yang M, et al. Attenuation of sialylation augments antitumor immunity and improves response to immunotherapy in ovarian cancer [J]. Cancer Res, 2023, 83(13): 2171-2186.
|
| 24 |
pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications [J]. Nat Rev Cancer, 2015, 15(9): 540-555.
|
| 25 |
Xu G, Chen J, Wang G, et al. Resveratrol inhibits the tumorigenesis of follicular thyroid cancer via ST6GAL2-regulated activation of the hippo signaling pathway [J]. Mol Ther Oncolytics, 2020, 16: 124-133.
|
| 26 |
Bakhit M, Fujii M. Bioinformatic analysis of gene expression related to sialic acid biosynthesis in patients with medulloblastoma [J]. Cureus,2024, 16(5): e59997.
|
| 27 |
Castellana B, Escuin D, peiró G, et al. ASpN and GJB2 are implicated in the mechanisms of invasion of ductal breast carcinomas [J]. J Cancer,2012, 3: 175-183.
|
| 28 |
Liu R J, Cao X, Liang YJ, et al. ST6GAL2 is a novel prognostic biomarker and its expression correlates to immune cell infiltration in hepatocellular carcinoma [J]. Hepatology, 2022, 76: S1339-S.
|
| 29 |
Bickeböller M, Tagscherer KE, Kloor M, et al. Functional characterization of the tumor-suppressor MARCKS in colorectal cancer and its association with survival [J]. Oncogene, 2015, 34(9): 1150-1159.
|
| 30 |
Chen E, Li Q, Wang H, et al. MiR-92a promotes tumorigenesis of colorectal cancer, a transcriptomic and functional based study [J]. Biomed Pharmacother, 2018, 106: 1370-1377.
|
| 31 |
He Y, Lu F, Jiang C, et al. Cold atmospheric plasma stabilizes mismatch repair for effective, uniform treatment of diverse colorectal cancer cell types [J]. Sci Rep, 2024, 14(1): 3599.
|
| 32 |
Vilar E, Bartnik CM, Stenzel SL, et al. MRE11 deficiency increases sensitivity to poly(ADp-ribose) polymerase inhibition in microsatellite unstable colorectal cancers [J]. Cancer Res, 2011, 71(7): 2632-2642.
|